Priority Review roundup: Roche-PTC, Intercept, Zogenix

FDA granted Priority Review to a trio of compounds Monday, accepting NDAs from partners Roche and PTC, as well as Intercept and Zogenix to treat neurological and hepatic diseases.

Risdiplam from Roche (SIX:ROG; OTCQX:RHHBY) and PTC Therapeutics Inc. (NASDAQ:PTCT) was granted Priority Review to treat spinal muscular atrophy (SMA).

Read the full 489 word article

User Sign In